Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy.

AIDS research and human retroviruses - 20 Mar 2001

Bai J, Rossi J, Akkina R

Abstract excerpt

HIV-1 infection of susceptible cells is mediated by the specific interaction of viral envelope glycoproteins with the cell surface CD4 receptor and a chemokine coreceptor, CCR5 or CXCR4. Individuals with a CCR5 genetic defect show resistance to HIV-1 infection, indicating that downregulation of CCR5 expression on target cells can prevent viral infection. In previous studies we demonstrated the utility of an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CCR5 Receptor Antagonists
Share to Chemokines, CC
Share to Genetic Therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hematopoietic Stem Cells

Share to Immunophenotyping

Share to Receptors, CCR5

Share to RNA, Catalytic

Share to Transduction, Genetic

Source

Identifiers

PMID: 11282007
DOI: 10.1089/088922201750102427

Genes

CCR5
CXCR4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy.PMID 11282007Read ↗

RNAi in Combination with a Ribozyme and TAR Decoy for Treatment of HIV Infection in Hematopoietic Cell Gene TherapySemantic proximity Read ↗

CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.Semantic proximity Read ↗

Targeted disruption of the CCR5 gene in human hematopoietic stem cells stimulated by peptide nucleic acids.Semantic proximity Read ↗

Preclinical Evaluation of a Novel TALEN Targeting CCR5 Confirms Efficacy and Safety in Conferring Resistance to HIV‐1 InfectionSemantic proximity Read ↗

Novel lentiviral vectors with mutated reverse transcriptase for mRNA delivery of TALE nucleases.Semantic proximity Read ↗

CRISPR/Cas9-mediated gene disruption of endogenous co-receptors confers broad resistance to HIV-1 in human primary cells and humanized miceSemantic proximity Read ↗

Efficient modification of <i>CCR5</i> in primary human hematopoietic cells using a megaTAL nuclease and AAV donor templateSemantic proximity Read ↗

Generation of an HIV Resistant T-cell Line by Targeted “Stacking” of Restriction FactorsSemantic proximity Read ↗

Inhibition of HIV‐1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transductionSemantic proximity Read ↗

Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infectionSemantic proximity Read ↗

Ribozyme therapy for HIV infectionSemantic proximity Read ↗

High frequency CCR5 editing in human hematopoietic stem progenitor cells protects xenograft mice from HIV infectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.